Biora Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Biora Therapeutics, Inc. (BIORQ) is a clinical-stage biotechnology company that develops innovative smart pill platforms for oral biotherapeutics delivery, primarily targeting gastrointestinal diseases and chronic conditions requiring systemic treatments. The company offers two core platforms: NaviCap, a targeted oral delivery system that delivers therapeutics directly to specific sites in the gastrointestinal tract to improve outcomes for inflammatory bowel diseases such as ulcerative colitis; and BioJet, a systemic oral delivery platform enabling needle-free administration of large molecules to replace injections for better management of chronic diseases. These platforms combine advanced drug-device technologies with smart capsule systems designed for precision medicine applications in the United States. Founded in 2010 as Ascendant MDx, Inc. in San Diego, California, the company rebranded to Progenity, Inc. in 2013, underwent a strategic pivot to therapeutics in 2021, and changed its name to Biora Therapeutics, Inc. in April 2022 to emphasize its drug delivery pipeline. Headquartered at 4330 La Jolla Village Drive in San Diego, it operates in the biological products industry with approximately 58 employees and focuses on partnerships with pharmaceutical collaborators for broader therapeutic applications. In recent developments, Biora Therapeutics secured a $16 million multiple-draw funding facility from existing convertible noteholders in August 2024 to bridge to anticipated large pharma partnerships, driven by interest in its BioJet platform and positive Phase 1 clinical results for NaviCap-based BT-600. The company reported promising data from its BT-600 trial for colon-targeted delivery, presented at medical conferences, and planned a Phase 1b trial for active ulcerative colitis by late 2024. However, facing financial pressures, it filed for Chapter 11 bankruptcy reorganization on December 27, 2024, which converted to Chapter 7 liquidation on May 27, 2025.
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Biora Therapeutics Announces Funding Agreement with Existing Investors
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules